Lower riskDrug recall · FDA · Published February 12, 2024
MCKESSON CABTREO Gel Recall: Storage Temperature Risk
MCKESSON recalls CABTREO topical gel due to improper storage causing potential product degradation. This prescription-only acne treatment may be unsafe if not kept refrigerated.
CGMP Deviations: Product was stored outside labeled storage temperature requirements. Product was exposed to controlled room temperature environment instead of remaining refrigerated.
Take action
Contact the company
📍Recalling firmMCKESSON CORPORATION6555 NORTH STATE HIGHWA · IRVING, TX 75039
“MCKESSON CABTREO Gel Recall: Storage Temperature Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32820-mckesson-cabtreo-gel-recall-storage-temperature-risk. Based on FDA recall #D-0347-2024 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0347-2024%22&limit=1).
The FDA announced on Feb. 12, 2024, that McKesson Corporation voluntarily recalled CABTREO topical gel due to CGMP deviations involving improper storage temperatures. The agency classified the recall as Class II.
How to tell if you have it
Brand: MCKESSON
Product: CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1%
NDC: 0187-0006-25
Lot code: 7001796
Expiration date: 05/31/2025
Net weight: 50g
Units affected: 42
Distribution: Nationwide in the US
The hazard
The product was stored outside labeled storage temperature requirements, exposing it to a controlled room temperature environment instead of remaining refrigerated. The FDA classified this as a Class II recall.
Context
GovInfoNow's records show McKesson Corporation has one other recall on record since Aug. 14, 2018, involving Megestrol Acetate Oral Suspension due to superpotent drug risk. Other recent recalls of similar products include McKesson Gemcitabine Injection Recall (June 10, 2026) and McKesson Recalls UDENYCA Injection Due to Temperature Abuse Risk (Jan. 16, 2026).
How to tell if you have this one
Check for CABTREO topical gel with lot number 7001796. This product is prescription-only and sold in 50g containers.
Brand
MCKESSON
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Verify the lot number on your CABTREO gel container to see if it matches 7001796.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide in the US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 8 months after the firm started it.
1Firm started the recall
2FDA classified it Class II
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0347-2024 (February 12, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0347-2024 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.